RESTON, Va., July 16, 2015 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, was awarded a prime contract by the U.S. Army Research Laboratory (ARL) to provide intelligence, surveillance and reconnaissance (ISR) concepts research and development (R&D). The multiple-award cost-plus fixed-fee indefinite-delivery indefinite-quantity contract has a five-year period of performance and a total contract value of approximately $49 million for all awardees. Work will be performed primarily at the ARL in Adelphi, Md. Leidos is one of seven awardees eligible to compete for task orders under the contract.
The ARL's mission is to discover, innovate, and transition science and technology to ensure dominant strategic land power. Under the contract, Leidos will have the opportunity to provide ISR R&D, including operational, program management, technical, engineering, integration, and program and product support services. Services will encompass a wide variety of advanced technology support to include analysis, studies, development, design, and demonstration of innovative ISR concepts and prototype technologies.
"We look forward to providing the Army Research Laboratory advanced technology support and innovative ISR concepts to increase technical performance, improve reliability and reduce costs of existing products and systems," said Leidos Group President, John Fratamico. "Leidos is proud to continue supporting the Army Research Laboratory and further our commitment to strengthening national defense."
About Leidos Leidos is a science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 19,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.06 billion for its fiscal year ended January 30, 2015. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 30, 2015, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.